Aduro BioTech

Aduro Biotech | Engineered Immunotherapy for Cancer.

Launch date

2000

Market cap

Enterprise valuation

Berkeley California (HQ)

Revenues, earnings & profits over time

EUR	2016	2017	2018	2019
R&D budget	35.0m	60.0m	46.0m	38.0m

Source: Dealroom estimates

Date	Investors	Amount	Round
May 2008	N/A	$3.9m	Series A
Dec 2008	N/A	$1.8m	Convertible
Nov 2009	N/A	$1.2m	Early VC
Apr 2011	Morningside Group	N/A	Series B
Dec 2011	N/A	N/A	Debt
Jan 2013	N/A	N/A	Series B
Sep 2013	N/A	N/A	Convertible
Jun 2014	Morningside Group Johnson & Johnson Development Corporation	N/A	Series C
Jan 2015	Fidelity Investments Morningside Group Foresite Capital Janus Capital Group OrbiMed Jennison Associates Franklin Advisors	$51.4m	Series D
Apr 2015	Novartis Amblyotech	$25.0m	Post IPO Equity
Apr 2015	N/A	$119m	IPO
Oct 2020	Chinook Therapeutics	N/A	Merger
May 2024*	N/A	$2.5m	Private Placement VC
Total Funding		€55.3m

Tech stackLearn more about the technologies and tools that this company uses.

ACQUISITION by Novartis Jun 2023

Financials